ChromaDex, Inc. Opens New State-of-the-Art Research And Development Center In Longmont
R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites
JANUARY 5, 2017, IRVINE, CALIFORNIA – Today, ChromaDex Corporation (https://www.chromadex.com/) (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, is announcing the grand opening of its new 10,000-square-foot research and development center in Longmont, Colorado.
With nearly $1 million invested to renovate the space into a state-of-the-art facility, it now includes multiple laboratories which will support the discovery and development of novel molecules and compounds to add to ChromaDex’s proprietary ingredient portfolio, while also allowing for the expansion of ChromaDex’s analytical service offerings at its Boulder, Colorado, location.
The grand opening ceremony will be held today, Thursday, January 5th, with Longmont Mayor, Dennis L. Coombs, as well as members from the Longmont Economic Development Partnership and ChromaDex Corporation in attendance.
Chief Operating Officer, Troy Rhonemus commented, “The construction and opening of the Longmont R&D facility marks an important growth milestone for ChromaDex. This facility is a critical asset that will enable us to acquire additional ingredient intellectual property, and continue our leadership in the identification and development of additional NAD+ metabolites.”
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme in cellular metabolism. Published research suggests that many aging-related health challenges are linked to NAD+ deficiency. NAD+ and its metabolites such as Nicotinamide Riboside (NR) have been the focus of intense scientific research and popular news media coverage recently due to their believed roles in healthy aging and healthspan. NR has been shown to safely and effectively increase NAD+ in human subjects supported by published research in Nature Communications.
ChromaDex, being publicly traded on NASDAQ, gives the public an opportunity for investing in the business of science-based technologies for healthy aging and longevity. To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on NR. It has also has initiated over 100 collaborative studies with leading universities and research institutions such as the National Institute of Aging, MIT and the Scripps Research Institute representing an estimated $40-50 million in NR research. Most of ChromaDex’s recent revenue growth has come from its proprietary ingredients, in particular NIAGEN®, which is commercially manufactured NR by ChromaDex.
Frank Jaksch Jr., Founder and CEO of ChromaDex, stated, “These collaborative studies are a huge validation that NR is very much relevant to the research community, as many of these collaborations that started as preclinical animal studies are now being published in top tier peer-reviewed journals such as Nature, Science and Cell Metabolism. We are now moving into human clinical studies based on the preclinical success of NR.”
ChromaDex’s current proprietary ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. In addition to NIAGEN®, NR, ChromaDex also has pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal, and AnthOrigin™, naturally extracted anthocyanins in its portfolio of patented technologies.
For more information on ChromaDex, visit: https://www.chromadex.com/.
JANUARY 5, 2017, IRVINE, CALIFORNIA – Today, ChromaDex Corporation (https://www.chromadex.com/) (NASDAQ: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, is announcing the grand opening of its new 10,000-square-foot research and development center in Longmont, Colorado.
With nearly $1 million invested to renovate the space into a state-of-the-art facility, it now includes multiple laboratories which will support the discovery and development of novel molecules and compounds to add to ChromaDex’s proprietary ingredient portfolio, while also allowing for the expansion of ChromaDex’s analytical service offerings at its Boulder, Colorado, location.
The grand opening ceremony will be held today, Thursday, January 5th, with Longmont Mayor, Dennis L. Coombs, as well as members from the Longmont Economic Development Partnership and ChromaDex Corporation in attendance.
Chief Operating Officer, Troy Rhonemus commented, “The construction and opening of the Longmont R&D facility marks an important growth milestone for ChromaDex. This facility is a critical asset that will enable us to acquire additional ingredient intellectual property, and continue our leadership in the identification and development of additional NAD+ metabolites.”
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme in cellular metabolism. Published research suggests that many aging-related health challenges are linked to NAD+ deficiency. NAD+ and its metabolites such as Nicotinamide Riboside (NR) have been the focus of intense scientific research and popular news media coverage recently due to their believed roles in healthy aging and healthspan. NR has been shown to safely and effectively increase NAD+ in human subjects supported by published research in Nature Communications.
ChromaDex, being publicly traded on NASDAQ, gives the public an opportunity for investing in the business of science-based technologies for healthy aging and longevity. To date, ChromaDex has invested millions in safety, toxicology and human clinical trials on NR. It has also has initiated over 100 collaborative studies with leading universities and research institutions such as the National Institute of Aging, MIT and the Scripps Research Institute representing an estimated $40-50 million in NR research. Most of ChromaDex’s recent revenue growth has come from its proprietary ingredients, in particular NIAGEN®, which is commercially manufactured NR by ChromaDex.
Frank Jaksch Jr., Founder and CEO of ChromaDex, stated, “These collaborative studies are a huge validation that NR is very much relevant to the research community, as many of these collaborations that started as preclinical animal studies are now being published in top tier peer-reviewed journals such as Nature, Science and Cell Metabolism. We are now moving into human clinical studies based on the preclinical success of NR.”
ChromaDex’s current proprietary ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. In addition to NIAGEN®, NR, ChromaDex also has pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal, and AnthOrigin™, naturally extracted anthocyanins in its portfolio of patented technologies.
For more information on ChromaDex, visit: https://www.chromadex.com/.